News articles about Oncobiologics (NYSE:ONS) have trended somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Oncobiologics earned a coverage optimism score of 0.09 on Accern’s scale. Accern also gave news headlines about the company an impact score of 46.5927170567767 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Oncobiologics (NYSE:ONS) opened at 1.35 on Tuesday. Oncobiologics has a 1-year low of $1.27 and a 1-year high of $4.56. The stock has a 50 day moving average price of $1.65 and a 200 day moving average price of $1.65. The stock’s market cap is $33.31 million.

Separately, Zacks Investment Research cut Oncobiologics from a “buy” rating to a “hold” rating in a research note on Friday, June 9th.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at

Oncobiologics Company Profile

Oncobiologics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing, manufacturing and commercializing biosimilar therapeutics. It is focused on monoclonal antibodies (mAbs) in the disease areas of immunology and oncology. The Company offers BioSymphony Platform.

Insider Buying and Selling by Quarter for Oncobiologics (NYSE:ONS)

Receive News & Stock Ratings for Oncobiologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics Inc and related stocks with our FREE daily email newsletter.